MEET BRIDGE MEDICINES
Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine.
RECENT NEWS
Barbara Evans2021-07-28T13:33:44-04:00
Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers
Barbara Evans2021-07-28T13:33:44-04:00July 28, 2021|
margaret2020-11-24T21:28:39-05:00
Bridge Medicines Announces Additional Funding of $10 Million from Inside Investors
margaret2020-11-24T21:28:39-05:00November 12, 2020|
margaret2020-11-24T20:53:23-05:00
Bridge Medicines Adds Small Molecule Inhibitors of Activated Factor XII to Pipeline
margaret2020-11-24T20:53:23-05:00September 21, 2020|
OUR PARTNERS
Loading...
-
The Rockefeller University
The Rockefeller University is the world’s leading biomedical research university and is dedicated to conducting innovative, high-quality research to improve the understanding of life for the benefit of humanity.
-
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center — the world’s oldest and largest private cancer center — has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 45 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.
-
Bay City Capital LLC
Bay City Capital LLC is a life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, largely focused on the development of breakthrough therapeutics.
-
Tri-Institutional Therapeutics Discovery Institute
TDI connects researchers from Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine with collaborators from across the globe to remove the barriers that impede drug discovery in academic settings. Together with our partner, Takeda, we enable the discovery of next-generation drugs by empowering our faculty with the tools, technology, and expertise to meet this extraordinary challenge.
-
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.
-
Deerfield Management Company
Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.
-
Weill Cornell Medicine
Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world. The doctors, scientists and faculty of all Weill Cornell facilities are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies.
WHAT ARE WE WORKING ON NOW?
Gain insight into transformational ideas and breakthrough research nurtured in our current pipeline.